Drugs / MCS110
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03742349 | Jan 2019 → Feb 2023 | triple-negative breast carcinoma | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT03285607 | Sep 2018 → Oct 2019 | breast cancer | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT03455764 | Sep 2018 → Sep 2023 | melanoma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT02807844 | Jun 2016 → Jun 2020 | endometrial carcinoma, melanoma, triple-negative breast carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT00757757 | Sep 2008 → Aug 2009 | metastatic carcinoma in the bone, prostate cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT03694977 | Jan → Dec 2019 | gastric cancer | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02435680 | Aug 2015 → Jan 2020 | triple-negative breast carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01643850 | Apr 2012 → Dec 2017 | tenosynovial giant cell tumor, diffuse type | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MCS110 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00757757 ↗ |
| Known as | lacnotuzumab | “lacnotuzumab (MCS110), a high-affinity, humanized monoclonal antibody directed against human CSF-1” PMID 38721402 ↗ May 2024 |
| Action | Inhibit | “Blocking the colony-stimulating factor 1 (CSF-1) signal on tumor-associated macrophages” PMID 38721402 ↗ May 2024 |
| Modality | Monoclonal antibody | “a high-affinity, humanized monoclonal antibody directed against human CSF-1” PMID 38721402 ↗ May 2024 |
| Route | Intravenous | “administered intravenously” NCT01643850 ↗ |
| Target | CSF1 | “directed against human CSF-1” PMID 38721402 ↗ May 2024 |